BioSpace News Archive

Thermo Fisher Scientific Inc., the world leader in serving science, has opened a new clinical and commercial ultra-cold facility in the EU, expanding its clinical trial network in Europe to help accelerate the development of advanced therapies.

QIAGEN announced the launch of the QIAstat-Dx Gastrointestinal Panel 2 in the United States.

Alligator Bioscience announced the publication of positive Phase 2 data on its lead drug candidate mitazalimab in first line metastatic pancreatic cancer in The Lancet Oncology.

Orion is participating in a project led by the University of Turku for which Business Finland recently granted 11.7M€ funding.

NeoImmuneTech, Inc., a T cell-focused therapeutics company, announced promising interim results of its major clinical trial NIT-110 of NT-I7, at the 2024 American Society of Clinical Oncology global meeting held in Chicago, from May 31 to June 4.

Bio-Thera Solutions Inc., a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for Avzivi®, a biosimilar monoclonal antibody referencing AVASTIN®.

Zura Bio Limited, a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, announced it will present data from its tibulizumab program exploring the clinical potential of the dual-pathway antibody in Sjogren’s syndrome and rheumatoid arthritis at EULAR 2024, June 12-15 in Vienna.

Amphastar Pharmaceuticals, Inc. announced that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 12:30 pm EST.

HighLife SAS, a medtech company focused on the development of a novel Trans-Septal Mitral Valve Replacement system to treat patients suffering from moderate to severe Mitral Regurgitation, announced that the U.S. Food and Drug Administration granted an Investigational Device Exemption to initiate a US Pivotal Study with its technology.

FibroGen, Inc. announced that Thane Wettig, Chief Executive Officer, will participate in a Fireside Chat at Goldman Sachs 45th Annual Global Healthcare Conference to be held in Miami, Florida on Monday, June 10, 2024, from 10:00-10:35 AM Eastern Time.